Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DNLI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.96B
- EPS (TTM)
- -$1.72
- Dividend yield
- None
- 52-week range
- 15.34 – 27.30
- Day range
- 17.92 – 18.85
- Volume / Avg
- 2.63M / 1.68M
- Beta
- —
- Shares outstanding
- 160.29M
52-week range
DNLI stock today
Denali Therapeutics (DNLI) closed at $18.45 on Nov 20, up 1.37% (+$0.25), versus the S&P 500's 3.70% decline. Shares are 32.4% below their 52-week high of $27.30, set on Jul 9, 2026 and 20.3% above the 52-week low of $15.34, in the middle of the past year's range. DNLI is up 11.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 2.5%.
Denali Therapeutics has posted a net loss over the last twelve months (EPS of -$1.72), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Denali Therapeutics
Company profileDenali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Ryan J. Watts Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 503
- IPO year
- 2017
- Website
- denalitherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Denali Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Denali Therapeutics reported a net loss of $512.5 million, compared with a loss of $422.8 million a year earlier. Diluted earnings per share came in at -$2.97.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.53M | $108.46M | $48.66M |
| Growth | — | -100.00% | +204.74% | +122.90% | -85.50% |
| Net income | $-512.54M | $-422.77M | $-145.22M | $-325.99M | $-290.58M |
| EPS (diluted) | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 |
Analyst forecast
ForecastConsensus (21 analysts)
strong_buy
Avg. price target
$35.82+94.15%
- Strong buy 2
- Buy 18
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.37 vs $-0.69
- Surprise
- +153.62%
DNLI news
All DNLI news- DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?NasdaqDNLI, BIIB, TAK
- Why is Denali Therapeutics stock surging today?Investing.com
- Denali Therapeutics Reports Third Quarter 2026 Financial ResultsNasdaq
- Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsGlobeNewswire
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology ProductGlobeNewswire
- Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026GlobeNewswire
- Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?NasdaqRARE, AMGN, DNLI
Denali Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ADMAADMA Biologics Inc | 13.17 | -1.27% | $2.92B | vs DNLI |
| VCELVericel Corporation | 57.52 | -1.27% | $2.94B | vs DNLI |
| IOVAIovance Biotherapeutics Inc. | 6.90 | -5.61% | $3.19B | vs DNLI |
| RLAYRelay Therapeutics Inc. | 16.12 | +1.32% | $3.56B | vs DNLI |
| TARSTarsus Pharmaceuticals Inc. | 73.01 | -6.00% | $3.60B | vs DNLI |
| BEAMBeam Therapeutics Inc. | 20.90 | -0.19% | $2.16B | vs DNLI |
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs DNLI |
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs DNLI |
Indexes, lists and sector
Denali Therapeutics stock FAQ
What is Denali Therapeutics's stock price today?
DNLI last traded at $18.45 as of Nov 20, 4:00 PM EST, up 1.37% on the day. Prices are delayed at least 15 minutes.
Who is Denali Therapeutics's CEO?
Dr. Ryan J. Watts Ph.D. is the chief executive officer of Denali Therapeutics Inc., which has about 503 employees.
What is the DNLI 52-week high?
The 52-week high for DNLI is $27.30 and the 52-week low is $15.34. The stock is currently 32.4% below its high.